Story HighlightsImmunityBio stock jumped after reporting that Anktiva sales surged nearly 700% year-over-year in 2025.
ImmunityBio Stock (IBRX) Rockets Higher after Reporting 700% Growth in Anktiva Sales - TipRanks
ImmunityBio ($IBRX) stock surged over 30% on Thursday after the company released preliminary 2025 results, which pointed to a 700% jump in Anktiva sales. The biotechnology company reported about $113
By:Radhika Saraogi
Source:Tipranks.com
Published:
Related News
Trump Tariff Threats Weigh on Asian Risk Appetite: Markets Wrap - Bloomberg.com
European and US stock futures fell and haven assets such as gold rallied after President Donald Trump proposed new levies on eight countries that have opposed his plans to acquire Greenland. The dollar weakened against most of its major peers.
Bloomberg•Anand Krishnamoorthy
Trump Tariff Threat to Weigh on Risk Sentiment, European Stocks - Bloomberg.com
US President Donald Trump’s announcement of new tariffs on eight European countries over Greenland weighed on risk sentiment as trading kicked off Monday.
Bloomberg•Farah Elbahrawy, Julien Ponthus
Sequoia to invest in Anthropic, breaking VC taboo on backing rivals: FT - TechCrunch
Sequoia Capital is reportedly joining a blockbuster funding round for Anthropic, the AI startup behind Claude, according to the Financial Times. It's a
TechCrunch•Connie Loizos